Nanobiotix S.A. ADR (NBTX) News
Filter NBTX News Items
NBTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NBTX News Highlights
- For NBTX, its 30 day story count is now at 2.
- Over the past 13 days, the trend for NBTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about NBTX are DEC.
Latest NBTX News From Around the Web
Below are the latest news stories about NANOBIOTIX SA that investors may wish to consider to help them evaluate NBTX as an investment opportunity.
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian MarketsPARIS and CAMBRIDGE, Mass., Dec. 26, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that partner LianBio has entered into an agreement with Janssen Pharmaceutica NV (“Janssen”), a Johnson & Johnson company, whereby LianBio has assigned to Janssen LianBio’s exclusive rights to develop and commercialize |
Voting Rights and Shares Capital of the CompanyIn accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares Outstanding1Total number of voting rightsTotal voting rights, theoretical2Total voting rights,exercisabl |
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.Aggregate gross proceeds of approximately €50.9 million (equivalent to approximately $53.8 million) received by NANOBIOTIX has increased to approximately €55.5 million (equivalent to approximately $58.7 million) extending its runway into mid’ 2025 PARIS and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities |
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update$2.5 billion global licensing, co-development, and commercialization agreement expands worldwide potential of novel radioenhancer NBTXR316.9 months median progression free survival (mPFS) and 23.1 months median overall survival (mOS) following radiotherapy-activated (RT) NBTXR3 in topline Study 102 Phase 1 data in head and neck cancer strengthens hypotheses for pivotal NANORAY-312 trial designPromising initial anti-tumor efficacy, median overall survival (mOS) of 23 months, 92% local disease con |
NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023Conference call and webcast scheduled for Tuesday, November 14, 2023, at 2:00 pm. CET / 8:00 am ETPARIS and CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its financial results for the third quarter ended September 30, 2023, on Monday, November 13, 2023, a |
NANOBIOTIX Announces Closing of Global OfferingPARIS and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the closing today (the “Closing”) of its global follow-on offering reserved to specified categories of investors, including after partial exercise by the underwriters of their option to purchase additional ordina |
NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6MNBTXR3-RT + anti-PD-1 NBTXR3-RT + anti-PD-1: ongoing discussions at Nanobiotix relating to this potential study in recurrent and/or metastatic head and neck cancers under consultation prior to continuing discussions with the FDA with the perspective of establishing a protocol for a pivotal study PARIS and CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-ba |
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55MPARIS and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the pricing of its previously announced global follow-on offering reserved to specified categories of investors, consisting of (i) an offering of 3,106,907 American Depositary Shares (“ADSs”), each representing o |
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash CovenantPARIS and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the launch, subject to market and other conditions, of an approximately $30.0 million global follow-on offering (representing approximately €28.4 million) reserved to specified categories of investors consisting |
NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023Strategic Collaborator-presented Phase 1 Pancreatic Cancer Data An ongoing Phase 1, collaborator-led study of NBTXR3 in locally advanced pancreatic cancer (LAPC) established a favorable safety profile and recommended dose23 months median Overall Survival (mOS) observed in 17 patients treated with cytotoxic chemotherapy followed by RT-activated NBTXR3 Review of an historical control from the same center as this Phase 1 in 243 patients with LAPC showed an mOS of 19.2 months in 144 patients who rec |